Fundraising FoxInvus — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Co-investorsPappas CapitalAberdare VenturesEcoR1 CapitalPolaris Partners
Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC).
BiotechHealthtechCambridge, US
Philip Kantoff(Chief Executive Officer, Co-Founder)inNeil Bander(Senior Scientific Advisor, Co-Founder)Alexander Brown(Executive Officer)inAndrew Davis(Chief Business and Strategy Officer)inElizabeth L. Montgomery(Chief People Officer)inEric M. Sullivan(Chief Financial Officer)in
Co-investorsOrbiMedRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.